Libby, Bhatt, Bonow et al. Braunwald’s heart disease. 12th ed. Elsevier Saunders; 2021.

Roth GA, Mensah GA, Johnson CO, et al. GBD-NHLBI-JACC global burden of cardiovascular diseases writing group. Global burden of cardiovascular diseases and risk factors, 1990–2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010. Erratum. In: J Am Coll Cardiol. 2021 Apr 20;77(15):1958–1959. https://doi.org/10.1016/j.jacc.2021.02.039.

Lévy S. Factors predisposing to the development of atrial fibrillation. Pacing Clin Electrophysiol. 1997;20(10 Pt 2):2670–4. https://doi.org/10.1111/j.1540-8159.1997.tb06115.x.

Article  PubMed  Google Scholar 

Sagris M, Vardas EP, Theofilis P, et al. Atrial fibrillation: pathogenesis, predisposing factors, and genetics. Int J Mol Sci. 2021;23(1):6. https://doi.org/10.3390/ijms23010006.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eleid MF, Nkomo VT, Pislaru SV, Gersh BJ. Valvular heart disease: new concepts in pathophysiology and therapeutic approaches. Annu Rev Med. 2023;27(74):155–70. https://doi.org/10.1146/annurev-med-042921-122533.

Article  CAS  Google Scholar 

Ding WY, Gupta D, Lip GYH. Atrial fibrillation and the prothrombotic state: revisiting Virchow’s triad in 2020. Heart. 2020;106(19):1463–8. https://doi.org/10.1136/heartjnl-2020-316977.

Article  PubMed  Google Scholar 

Bańka P, Wybraniec M, Bochenek T, et al. Influence of aortic valve stenosis and wall shear stress on platelets function. J Clin Med. 2023;12(19):6301. https://doi.org/10.3390/jcm12196301.

Article  PubMed  PubMed Central  Google Scholar 

Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events–European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014;16(1):6–14. https://doi.org/10.1093/europace/eut263.

Article  PubMed  Google Scholar 

Mekaj YH, Mekaj AY, Duci SB, et al. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;24(11):967–77. https://doi.org/10.2147/TCRM.S84210.

Article  Google Scholar 

Lip GYH, Collet JP, Caterina R, et al. ESC Scientific Document Group. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace. 2017;19(11):1757–1758. https://doi.org/10.1093/europace/eux240.

Fanaroff AC, Vora AN, Lopes RD. Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease. Eur Heart J Suppl. 2022;24(Suppl A):A19–31. https://doi.org/10.1093/eurheartj/suab151.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aimo A, Giugliano RP, De Caterina R. Non-Vitamin K Antagonist oral anticoagulants for mechanical heart valves: is the door still open? Circulation. 2018;138(13):1356–65. https://doi.org/10.1161/CIRCULATIONAHA.118.035612.

Article  CAS  PubMed  Google Scholar 

Thomas KL, Jackson LR 2nd, Shrader P, et al. Prevalence, characteristics, and outcomes of valvular heart disease in patients with atrial fibrillation: insights from the ORBIT-AF (outcomes registry for better informed treatment for atrial fibrillation). J Am Heart Assoc. 2017;6(12):e006475. https://doi.org/10.1161/JAHA.117.006475.

Article  PubMed  PubMed Central  Google Scholar 

Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):160S-198S. https://doi.org/10.1378/chest.08-0670.

Article  CAS  PubMed  Google Scholar 

Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e152S-e184S. https://doi.org/10.1378/chest.11-2295.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grymonprez M, Petrovic M, De Backer TL, et al. The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Thromb Haemost. 2024;124(2):135–48. https://doi.org/10.1055/s-0043-1769735.

Article  PubMed  Google Scholar 

Eggebrecht L, Nagler M, Göbel S, et al. Relevance of polypharmacy for clinical outcome in patients receiving vitamin K antagonists. J Am Geriatr Soc. 2019;67(3):463–70. https://doi.org/10.1111/jgs.15712.

Article  PubMed  Google Scholar 

Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131(7):492–501. https://doi.org/10.7326/0003-4819-131-7-199910050-00003.

Article  CAS  PubMed  Google Scholar 

Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89(2):635–41. https://doi.org/10.1161/01.cir.89.2.635.

Article  CAS  PubMed  Google Scholar 

Gateman D, Trojnar ME, Agarwal G. Time in therapeutic range: warfarin anticoagulation for atrial fibrillation in a community-based practice. Can Fam Physician. 2017;63(10):e425–31.

PubMed  PubMed Central  Google Scholar 

Eikelboom JW, Connolly SJ, Brueckmann M, et al. RE-ALIGN investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206–14. https://doi.org/10.1056/NEJMoa1300615.

Article  CAS  PubMed  Google Scholar 

Capodanno D, Collet JP, Dangas G, et al. Antithrombotic therapy after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2021;14(15):1688–703. https://doi.org/10.1016/j.jcin.2021.06.020.

Article  PubMed  Google Scholar 

Heestermans M, Poenou G, Hamzeh-Cognasse H, et al. A short history, their mechanism of action, pharmacology, and indications. Cells. 2022;11(20):3214. https://doi.org/10.3390/cells11203214.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. https://doi.org/10.1056/NEJMoa0905561.

Article  CAS  PubMed  Google Scholar 

Ezekowitz MD, Nagarakanti R, Noack H, et al. Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY trial (randomized evaluation of long-term anticoagulant therapy). Circulation. 2016;134(8):589–98. https://doi.org/10.1161/CIRCULATIONAHA.115.020950.

Article  CAS  PubMed  Google Scholar 

Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. https://doi.org/10.1056/NEJMoa1009638.

Article  CAS  PubMed  Google Scholar 

Breithardt G, Baumgartner H, Berkowitz SD, et al. ROCKET AF Steering Committee and Investigators. Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. Heart. 2016;102(13):1036–43. https://doi.org/10.1136/heartjnl-2015-308120.

Article  CAS  PubMed  Google Scholar 

Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. https://doi.org/10.1056/NEJMoa1107039.

Article  CAS  PubMed  Google Scholar 

Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation. 2015;132(8):624–32. https://doi.org/10.1161/CIRCULATIONAHA.114.014807.

Article  CAS  PubMed  Google Scholar 

Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104. https://doi.org/10.1056/NEJMoa1310907.

Article  CAS  PubMed  Google Scholar 

De Caterina R, Renda G, Carnicelli AP, et al. Valvular heart disease patients on e